NCT02648711 - Alternative Dosing for CRLX101(NLG207) Alone, With Avastin and With mFOLFOX6 in Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

October 17, 2017

Study Completion Date

May 7, 2018

Conditions

Solid Tumors

Interventions

DRUG

CRLX101

infusion CRLX101 weekly

DRUG

Bevacizumab

infusion weekly CRLX101 + bevacizumab biweekly

DRUG

mFOLFOX6

infusion weekly CRLX101 for 3 or every 4 weeks and in combination with bi-weekly mFOLFOX6

Trial Locations (3)

START Midwest/Cancer & Hematology Centers of Western Michigan, PC, Grand Rapids

MD Anderson Cancer Center, Houston

South Texas Accelerated Research Therapeutics (START), LLC, San Antonio